NCT00075400View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Recurrent Uterine SarcomaUterine Carcinosarcoma
Interventions
DRUG

imatinib mesylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00075400 - Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | Biotech Hunter | Biotech Hunter